Karol Magiera
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Karol Magiera has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Barbara Magiera
Prof. K. Gibiński University Clinical Center of the Medical University of Silesia in Katowice, Medyków 14, 40-752 Katowice, Poland
12 shared publications - Jakub Rybak
Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland
11 shared publications - Jan Ramian
Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medyków 18, 40-752 Katowice, Poland
10 shared publications - Piotr Bator
Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medyków 18, 40-752 Katowice, Poland
10 shared publications - Patrycja Rozwadowska
Department of Molecular Biology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medykow 18 Street, 40-752 Katowice, Poland
8 shared publications - Michał Razik
Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medyków 18, 40-752 Katowice, Poland
6 shared publications
Latest Publications
- Open Access
- 13 September 2024
- Published by VM Media Group sp. z o.o in Chirurgia Polska
- Vol. 25 (1-2) , 61-65
Migracja stent-graftu branchowego podczas implantacji u chorego leczonego z powodu piersiowobrzusznego tętniaka aorty
Branched endovascular aneurysm repair (bEVAR) are routinely used in clinical practice in patients with complex aortic anatomy. However, they can lead to a number of complications, notable among which are the risk of stent-graft migration and rotation. We present the case of a patient treated for a thoracoabdominal aortic aneurysm in whom, as a result of stent-graft rotation, the dedicating branch of the left renal artery was located in the exit of the superior mesenteric artery. Keywords: migration rotation branch stent-graft thoraco-abdominal aneurysm
- 13 September 2024
- Published by VM Media Group sp. z o.o in Chirurgia Polska
- Vol. 25 (1-2) , 61-65
Open AccessMigracja stent-graftu branchowego podczas implantacji u chorego leczonego z powodu piersiowobrzusznego tętniaka aorty
Branched endovascular aneurysm repair (bEVAR) are routinely used in clinical practice in patients with complex aortic anatomy. However, they can lead to a number of complications, notable among which are the risk of stent-graft migration and rotation. We present the case of a patient treated for a thoracoabdominal aortic aneurysm in whom, as a result of stent-graft rotation, the dedicating branch of the left renal artery was located in the exit of the superior mesenteric artery. Keywords: migration rotation branch stent-graft thoraco-abdominal aneurysm
- 3 September 2024
- Published by European Scientific Society in Archiv Euromedica
- Vol. 14 (4)
THE ROLE OF CORTISOL IN THE ETIOLOGY AND TREATMENT OF BRUXISM
Bruxism is an issue that has a major influence on both dental and general health. It is defined by the involuntary clenching and grinding of the teeth. Bruxism can present itself in two main ways: during sleep and during wakefulness. This study investigates the function of the stress hormone cortisol in the development and treatment of bruxism. Those who have bruxism often have elevated cortisol levels, which suggests a strong correlation between stress and bruxism episodes. The study examines the body of research, emphasizing the link between bruxism and hormone changes brought on by stress. It also looks at possible cortisol-management-based therapeutic approaches. Pharmacological therapy, lifestyle adjustments, and stress management strategies are examples of effective interventions. Comprehending the intricate relationship between bruxism and cortisol will aid medical professionals in creating all-encompassing therapy strategies that can ultimately enhance patient results and quality of life.
- 3 September 2024
- Published by European Scientific Society in Archiv Euromedica
- Vol. 14 (4)
THE ROLE OF CORTISOL IN THE ETIOLOGY AND TREATMENT OF BRUXISM
Bruxism is an issue that has a major influence on both dental and general health. It is defined by the involuntary clenching and grinding of the teeth. Bruxism can present itself in two main ways: during sleep and during wakefulness. This study investigates the function of the stress hormone cortisol in the development and treatment of bruxism. Those who have bruxism often have elevated cortisol levels, which suggests a strong correlation between stress and bruxism episodes. The study examines the body of research, emphasizing the link between bruxism and hormone changes brought on by stress. It also looks at possible cortisol-management-based therapeutic approaches. Pharmacological therapy, lifestyle adjustments, and stress management strategies are examples of effective interventions. Comprehending the intricate relationship between bruxism and cortisol will aid medical professionals in creating all-encompassing therapy strategies that can ultimately enhance patient results and quality of life.
- 3 September 2024
- Published by European Scientific Society in Archiv Euromedica
- Vol. 14 (4)
ADVANCES IN DIAGNOSIS AND TREATMENT OF CONGENITAL HEART DISEASE: A COMPREHENSIVE REVIEW
The purpose of this article is to provide a comprehensive review of recent advances in the diagnosis and treatment of congenital heart disease (CHD). CHD, which affects about 1% of live births worldwide, is still a major problem in pediatric cardiology. The most prevalent congenital cardiac defects—Ventricular Septal Defect (VSD), Tetralogy of Fallot (TOF), Coronary Artery Fistula, Coarctation of the Aorta (CoA), Aortic and Pulmonary Stenosis, Valve Insufficiency, Double Outlet Right Ventricle (DORV), Ebstein Anomaly, Transposition of the Great Arteries (TGA), Anomalous Venous Return, and Hypoplastic Left Heart Syndrome (HLHS) are all thoroughly examined in this review. The review examines current diagnostic and treatment strategies, highlighting the benefits, drawbacks, sensitivity, and specificity of several imaging modalities, including as CT, MRI, and echocardiography. It also discusses the historical evolution of treatment outcomes, emphasizing the tremendous advances in patient care and surgical procedures that have significantly mproved survival rates and quality of life for CHD patients.
- 3 September 2024
- Published by European Scientific Society in Archiv Euromedica
- Vol. 14 (4)
ADVANCES IN DIAGNOSIS AND TREATMENT OF CONGENITAL HEART DISEASE: A COMPREHENSIVE REVIEW
The purpose of this article is to provide a comprehensive review of recent advances in the diagnosis and treatment of congenital heart disease (CHD). CHD, which affects about 1% of live births worldwide, is still a major problem in pediatric cardiology. The most prevalent congenital cardiac defects—Ventricular Septal Defect (VSD), Tetralogy of Fallot (TOF), Coronary Artery Fistula, Coarctation of the Aorta (CoA), Aortic and Pulmonary Stenosis, Valve Insufficiency, Double Outlet Right Ventricle (DORV), Ebstein Anomaly, Transposition of the Great Arteries (TGA), Anomalous Venous Return, and Hypoplastic Left Heart Syndrome (HLHS) are all thoroughly examined in this review. The review examines current diagnostic and treatment strategies, highlighting the benefits, drawbacks, sensitivity, and specificity of several imaging modalities, including as CT, MRI, and echocardiography. It also discusses the historical evolution of treatment outcomes, emphasizing the tremendous advances in patient care and surgical procedures that have significantly mproved survival rates and quality of life for CHD patients.
- 1 July 2024
- Published by European Scientific Society in Archiv Euromedica
- Vol. 14 (3)
LUNG CANCER - RISK FACTORS AND PREVENTION STRATEGIES - OVERVIEW OF THE LITERATURE
Europäische Wissenschaftliche Gesellschaft Home About the Journal Peer Review Editorial Board For Authors Reviewer Recognition Archive Contact Impressum EWG e.V. Elektronische Zeitschriftbibliotek Logo Bielefeld Academic Search Engine Logo Erfolgreich durch internationale Zusammenarbeit ONCOLOGY Cite as: Archiv EuroMedica. 2024. 14; 3. DOI 10.35630/2024/14/3.344 Received 25 April 2024; Accepted 15 June 2024; Published 19 June 2024 LUNG CANCER - RISK FACTORS AND PREVENTION STRATEGIES - OVERVIEW OF THE LITERATURE Jakub Rybak1email orcid id logo, Barbara Magiera2orcid id logo, Karol Magiera1orcid id logo, Martyna Grabowska-Szczurek3orcid id logo, Alicja Grabarczyk4 orcid id logo, Piotr Bator1 orcid id logo, Michał Razik1 orcid id logo, Patrycja Rozwadowska1 orcid id logo, Karol Wielgus5 orcid id logo 1Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland 2Prof. K. Gibiński University Clinical Center of the Medical University of Silesia in Katowice, Poland 3The Hospital of the Bonifratres of St. John Grand in Cracow, Poland 4Students’ Scientific Society, Department of Gynecology and Obstetrics in Katowice, Medical University of Silesia, Katowice, Poland 5Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland download article (pdf) rybakjak@gmail.com ABSTRACT Introduction and purpose: Lung cancer is the second most common cancer worldwide. The aim of this study is to analyze the key modifiable and non-modifiable risk factors associated with the development of lung cancer and to discuss existing prevention strategies. Materials and methods: A literature review was conducted using the "PubMed" database with the keywords "lung cancer", "lung cancer risk factors", "lung cancer prevention”. Results: Lung cancer risk factors can be divided into two groups: modifiable and non-modifiable. Modifiable risk factors include: smoking, radon, diet, chronic lung diseases, asbestos and diesel fumes. Non-modifiable risk factors include: age, race, genetic factors and gender. In primary prevention of lung cancer it is important to reduce exposure to risk factors, especially cigarette smoke. Screening using low-dose computed tomography plays a major role in secondary prevention. Conclusion: Lung cancer is one of the most frequent malignant tumors. Over the years, enormous progress has been made in the fight against lung cancer. Despite a large reduction in smoking prevalence, cigarette smoking remains the most important risk factor of lung cancer. Several other factors have been identified, with e.g. asbestosis exposure and air pollutants being among top-5 risk factors with the highest impact. Effective methods of primary and secondary prevention such as health campaigns and screening tests have led to a reduction in the incidence of lung cancer. Smoking cessation and low-dose chest CT screening were proven to be the most effective in the lung cancer prevention. However, lung cancer remains the most common cause of death in cancer patients so further research and effective and practical public health policy are crucial in decreasing incidence and mortality.
- 1 July 2024
- Published by European Scientific Society in Archiv Euromedica
- Vol. 14 (3)
LUNG CANCER - RISK FACTORS AND PREVENTION STRATEGIES - OVERVIEW OF THE LITERATURE
Europäische Wissenschaftliche Gesellschaft Home About the Journal Peer Review Editorial Board For Authors Reviewer Recognition Archive Contact Impressum EWG e.V. Elektronische Zeitschriftbibliotek Logo Bielefeld Academic Search Engine Logo Erfolgreich durch internationale Zusammenarbeit ONCOLOGY Cite as: Archiv EuroMedica. 2024. 14; 3. DOI 10.35630/2024/14/3.344 Received 25 April 2024; Accepted 15 June 2024; Published 19 June 2024 LUNG CANCER - RISK FACTORS AND PREVENTION STRATEGIES - OVERVIEW OF THE LITERATURE Jakub Rybak1email orcid id logo, Barbara Magiera2orcid id logo, Karol Magiera1orcid id logo, Martyna Grabowska-Szczurek3orcid id logo, Alicja Grabarczyk4 orcid id logo, Piotr Bator1 orcid id logo, Michał Razik1 orcid id logo, Patrycja Rozwadowska1 orcid id logo, Karol Wielgus5 orcid id logo 1Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland 2Prof. K. Gibiński University Clinical Center of the Medical University of Silesia in Katowice, Poland 3The Hospital of the Bonifratres of St. John Grand in Cracow, Poland 4Students’ Scientific Society, Department of Gynecology and Obstetrics in Katowice, Medical University of Silesia, Katowice, Poland 5Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland download article (pdf) rybakjak@gmail.com ABSTRACT Introduction and purpose: Lung cancer is the second most common cancer worldwide. The aim of this study is to analyze the key modifiable and non-modifiable risk factors associated with the development of lung cancer and to discuss existing prevention strategies. Materials and methods: A literature review was conducted using the "PubMed" database with the keywords "lung cancer", "lung cancer risk factors", "lung cancer prevention”. Results: Lung cancer risk factors can be divided into two groups: modifiable and non-modifiable. Modifiable risk factors include: smoking, radon, diet, chronic lung diseases, asbestos and diesel fumes. Non-modifiable risk factors include: age, race, genetic factors and gender. In primary prevention of lung cancer it is important to reduce exposure to risk factors, especially cigarette smoke. Screening using low-dose computed tomography plays a major role in secondary prevention. Conclusion: Lung cancer is one of the most frequent malignant tumors. Over the years, enormous progress has been made in the fight against lung cancer. Despite a large reduction in smoking prevalence, cigarette smoking remains the most important risk factor of lung cancer. Several other factors have been identified, with e.g. asbestosis exposure and air pollutants being among top-5 risk factors with the highest impact. Effective methods of primary and secondary prevention such as health campaigns and screening tests have led to a reduction in the incidence of lung cancer. Smoking cessation and low-dose chest CT screening were proven to be the most effective in the lung cancer prevention. However, lung cancer remains the most common cause of death in cancer patients so further research and effective and practical public health policy are crucial in decreasing incidence and mortality.
- 1 July 2024
- Published by European Scientific Society in Archiv Euromedica
- Vol. 14 (3)
CARDIOPROTECTIVE PROPERTIES OF SGLT2-INHIBITORS
Due to its high mortality rate, heart failure (HF) presents a substantial worldwide health burden that calls for efficient treatment approaches. Inhibitors of the sodium-glucose co-transporter 2 (SGLT2) have become essential treatments for heart failure in all left ventricular ejection fraction (LVEF) levels. Their processes, which include enhanced metabolic efficiency and ventricular loading circumstances, present encouraging results. The effectiveness of SGLT2 inhibitors, dapagliflozin and empagliflozin, in lowering cardiovascular mortality and heart failure hospitalizations in heart failure patients with reduced, mildly reduced, and preserved ejection fraction has been shown in several clinical trials, including DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved, and DELIVER. These results represent a revolutionary development in the treatment of HF, emphasizing the use of SGLT2 inhibitors in comprehensive treatments, regardless of renal function or diabetes state.
- 1 July 2024
- Published by European Scientific Society in Archiv Euromedica
- Vol. 14 (3)
CARDIOPROTECTIVE PROPERTIES OF SGLT2-INHIBITORS
Due to its high mortality rate, heart failure (HF) presents a substantial worldwide health burden that calls for efficient treatment approaches. Inhibitors of the sodium-glucose co-transporter 2 (SGLT2) have become essential treatments for heart failure in all left ventricular ejection fraction (LVEF) levels. Their processes, which include enhanced metabolic efficiency and ventricular loading circumstances, present encouraging results. The effectiveness of SGLT2 inhibitors, dapagliflozin and empagliflozin, in lowering cardiovascular mortality and heart failure hospitalizations in heart failure patients with reduced, mildly reduced, and preserved ejection fraction has been shown in several clinical trials, including DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved, and DELIVER. These results represent a revolutionary development in the treatment of HF, emphasizing the use of SGLT2 inhibitors in comprehensive treatments, regardless of renal function or diabetes state.
- Open Access
- 22 May 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 71, 49418
SGLT2-Inhibitors - significant role in Heart Failure treatment
Heart failure (HF), which has a high morbidity and mortality rate, is nevertheless a common and crippling ailment, especially in older populations. The complicated pathophysiology of heart failure (HF), which includes oxidative stress, endothelial dysfunction, fibrosis, and inflammation, is frequently not sufficiently treated despite advances in medication. Inhibitors of the sodium-glucose co-transporter 2 (SGLT2) have become a key treatment for HF in patients with varying left ventricular ejection fractions (LVEF). SGLT2 inhibitors have been shown in recent clinical trials to considerably lower hospitalization rates for heart failure, cardiovascular mortality, and all-cause mortality. The mechanisms of SGLT2 inhibitors, such as better ventricular loading, increased heart metabolic efficiency, and decreased inflammation and necrosis, are covered in this review. Additionally, we provide an overview of four important clinical trials—DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved, and DELIVER—highlighting their effectiveness in lowering unfavourable cardiovascular outcomes for patients with heart failure who have preserved (HFpEF), slightly reduced (HFmrEF), or reduced (HFrEF). The results validate the need for SGLT2 inhibitors in all-inclusive HF treatment plans by highlighting their adaptability and safety in a range of clinical contexts.
- 22 May 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 71, 49418
Open AccessSGLT2-Inhibitors - significant role in Heart Failure treatment
Heart failure (HF), which has a high morbidity and mortality rate, is nevertheless a common and crippling ailment, especially in older populations. The complicated pathophysiology of heart failure (HF), which includes oxidative stress, endothelial dysfunction, fibrosis, and inflammation, is frequently not sufficiently treated despite advances in medication. Inhibitors of the sodium-glucose co-transporter 2 (SGLT2) have become a key treatment for HF in patients with varying left ventricular ejection fractions (LVEF). SGLT2 inhibitors have been shown in recent clinical trials to considerably lower hospitalization rates for heart failure, cardiovascular mortality, and all-cause mortality. The mechanisms of SGLT2 inhibitors, such as better ventricular loading, increased heart metabolic efficiency, and decreased inflammation and necrosis, are covered in this review. Additionally, we provide an overview of four important clinical trials—DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved, and DELIVER—highlighting their effectiveness in lowering unfavourable cardiovascular outcomes for patients with heart failure who have preserved (HFpEF), slightly reduced (HFmrEF), or reduced (HFrEF). The results validate the need for SGLT2 inhibitors in all-inclusive HF treatment plans by highlighting their adaptability and safety in a range of clinical contexts.
- 27 February 2024
- Published by European Scientific Society in Archiv Euromedica
- Vol. 14 (1)
ANNURCA APPLE EXTRACT - A BREAKTHROUGH IN ALOPECIA PHYTOTHERAPY: A LITERATURE REVIEW
ANNURCA APPLE EXTRACT - A BREAKTHROUGH IN ALOPECIA PHYTOTHERAPY: A LITERATURE REVIEW - Archiv-EuroMedica
- 27 February 2024
- Published by European Scientific Society in Archiv Euromedica
- Vol. 14 (1)
ANNURCA APPLE EXTRACT - A BREAKTHROUGH IN ALOPECIA PHYTOTHERAPY: A LITERATURE REVIEW
ANNURCA APPLE EXTRACT - A BREAKTHROUGH IN ALOPECIA PHYTOTHERAPY: A LITERATURE REVIEW - Archiv-EuroMedica
- Open Access
- 19 February 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 61, 155-166
Effects of red wine on cardiovascular diseases
Introduction and purpose: The purpose of this scientific paper is to review the current knowledge of the effects of red wine on human health, particularly with regard to cardiovascular disease. State of Knowledge: Since the 1990s, red wine has gained its status as a health-promoting alcohol through the French Paradox - when drunk in moderate amounts, it protects against cardiovascular disease. The authors have collected scientific papers on the health effects of alcohol, red wine and resveratrol-a polyphenol that is the main component with health-promoting effects of wine. On their basis, they analyzed the assumptions of the positive effects of wine reaching inconclusive conclusions. Summary: Despite the fact that both ethanol and resveratrol have a positive effect in in vitro studies, in population studies their effect is much less significant, either because the negative behavioral-health effects in the case of ethanol are omitted or the actual effective doses of resveratrol are omitted.
- 19 February 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 61, 155-166
Open AccessEffects of red wine on cardiovascular diseases
Introduction and purpose: The purpose of this scientific paper is to review the current knowledge of the effects of red wine on human health, particularly with regard to cardiovascular disease. State of Knowledge: Since the 1990s, red wine has gained its status as a health-promoting alcohol through the French Paradox - when drunk in moderate amounts, it protects against cardiovascular disease. The authors have collected scientific papers on the health effects of alcohol, red wine and resveratrol-a polyphenol that is the main component with health-promoting effects of wine. On their basis, they analyzed the assumptions of the positive effects of wine reaching inconclusive conclusions. Summary: Despite the fact that both ethanol and resveratrol have a positive effect in in vitro studies, in population studies their effect is much less significant, either because the negative behavioral-health effects in the case of ethanol are omitted or the actual effective doses of resveratrol are omitted.
- Open Access
- 17 February 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 61, 129-139
Fertility Preservation Strategies in Cancer Patients: A Comprehensive Review
Introduction and purpose. Preserving fertility is crucial for cancer patients, aligning with advancements in oncology. As survival rates improve, addressing treatment-related late effects gains importance. Many young patients, aware of therapy toxicity, consider future conception chances, impacting treatment decisions. With a trend toward delayed childbirth and a growing population facing unplanned family planning disruptions, the demand for fertility preservation is expected to rise. This paper provides a brief review of available methods for preserving fertility in cancer patients. State of knowledge. Freezing semen in liquid nitrogen vapor is a standard method for preserving reproductive potential in male cancer patients. Shielding during total-body radiation limits testicular volume reduction, indicating less damage to the germinal epithelium. Hormone suppression treatments are not protective in male cancer patients. Oocyte and embryo cryopreservation are considered secure methods before anticancer treatments, with oocyte cryopreservation being preferred for post-pubertal women. Ovarian tissue cryopreservation remains an alternative method without preliminary treatment, suitable when time is insufficient for ovarian stimulation. Ovarian transposition beyond the intended radiation area, performed laparoscopically, can retain ovarian function. GnRH agonist administration before and during chemotherapy aims to minimize the likelihood of premature ovarian insufficiency. Summary. Advancements in fertility preservation for cancer patients, ranging from traditional cryopreservation to innovative methods like ovarian tissue preservation, highlight a commitment to empowering individuals facing cancer diagnoses. Ongoing research expands possibilities, ensuring a diverse range of strategies that offer tangible and hopeful prospects at the intersection of cancer and reproductive health.
- 17 February 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 61, 129-139
Open AccessFertility Preservation Strategies in Cancer Patients: A Comprehensive Review
Introduction and purpose. Preserving fertility is crucial for cancer patients, aligning with advancements in oncology. As survival rates improve, addressing treatment-related late effects gains importance. Many young patients, aware of therapy toxicity, consider future conception chances, impacting treatment decisions. With a trend toward delayed childbirth and a growing population facing unplanned family planning disruptions, the demand for fertility preservation is expected to rise. This paper provides a brief review of available methods for preserving fertility in cancer patients. State of knowledge. Freezing semen in liquid nitrogen vapor is a standard method for preserving reproductive potential in male cancer patients. Shielding during total-body radiation limits testicular volume reduction, indicating less damage to the germinal epithelium. Hormone suppression treatments are not protective in male cancer patients. Oocyte and embryo cryopreservation are considered secure methods before anticancer treatments, with oocyte cryopreservation being preferred for post-pubertal women. Ovarian tissue cryopreservation remains an alternative method without preliminary treatment, suitable when time is insufficient for ovarian stimulation. Ovarian transposition beyond the intended radiation area, performed laparoscopically, can retain ovarian function. GnRH agonist administration before and during chemotherapy aims to minimize the likelihood of premature ovarian insufficiency. Summary. Advancements in fertility preservation for cancer patients, ranging from traditional cryopreservation to innovative methods like ovarian tissue preservation, highlight a commitment to empowering individuals facing cancer diagnoses. Ongoing research expands possibilities, ensuring a diverse range of strategies that offer tangible and hopeful prospects at the intersection of cancer and reproductive health.
- Open Access
- 16 February 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 61, 73-86
Anticancer properties of berberine - analysis of the latest reports
Introduction and purpose: Berberine is a plant alkaloid that naturally occurs in the fruits of common barberry (Berberis vulgaris). This alkaloid has long been used in natural medicine. It exhibits a range of bioactivities, such as antioxidant, anti-inflammatory, antidiabetic, anti-edema, and antimicrobial actions. Through the promising therapeutic effects of berberine in metabolic syndrome, as well as its impact on carcinogenesis, this compound is beginning to play a significant role in preventive medicine. Recently, particular attention has been paid to the anticancer properties of berberine, which are based on many biochemical pathways, particularly its pro-apoptotic and anti-inflammatory action. The study aimed to review the anticancer mechanisms of berberine and summarize them about individual cancers. State of knowledge: The article reviews the current literature on the anticancer properties of berberine for individual cancers, focusing primarily on its molecular mechanisms of action. In addition, the potential of berberine as a promising candidate forming the basis for drug production and its use in preventive medicine was analyzed. Summary: In summary, many studies have shown that berberine exhibits anticancer activity in many types of cancers, including breast, lung, stomach, liver, colorectal, ovarian, cervical, and prostate cancers. Berberine inhibits the growth of cancer cells, limits metastases, induces apoptosis, stimulates autophagy, and enhances the effectiveness of anticancer drugs. Despite its potential as a promising candidate for drug production, there are currently no approved pure berberine preparations for the treatment of specific ailments. Research on its effectiveness and safety is still ongoing.
- 16 February 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 61, 73-86
Open AccessAnticancer properties of berberine - analysis of the latest reports
Introduction and purpose: Berberine is a plant alkaloid that naturally occurs in the fruits of common barberry (Berberis vulgaris). This alkaloid has long been used in natural medicine. It exhibits a range of bioactivities, such as antioxidant, anti-inflammatory, antidiabetic, anti-edema, and antimicrobial actions. Through the promising therapeutic effects of berberine in metabolic syndrome, as well as its impact on carcinogenesis, this compound is beginning to play a significant role in preventive medicine. Recently, particular attention has been paid to the anticancer properties of berberine, which are based on many biochemical pathways, particularly its pro-apoptotic and anti-inflammatory action. The study aimed to review the anticancer mechanisms of berberine and summarize them about individual cancers. State of knowledge: The article reviews the current literature on the anticancer properties of berberine for individual cancers, focusing primarily on its molecular mechanisms of action. In addition, the potential of berberine as a promising candidate forming the basis for drug production and its use in preventive medicine was analyzed. Summary: In summary, many studies have shown that berberine exhibits anticancer activity in many types of cancers, including breast, lung, stomach, liver, colorectal, ovarian, cervical, and prostate cancers. Berberine inhibits the growth of cancer cells, limits metastases, induces apoptosis, stimulates autophagy, and enhances the effectiveness of anticancer drugs. Despite its potential as a promising candidate for drug production, there are currently no approved pure berberine preparations for the treatment of specific ailments. Research on its effectiveness and safety is still ongoing.